Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+17.3%
5Y CAGR+42.4%
Year-over-Year Change
Research and development spending
3Y CAGR
+17.3%/yr
Annual compound
5Y CAGR
+42.4%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
5.9x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $137.32M | +13.0% |
| 2024 | $121.56M | +15.7% |
| 2023 | $105.05M | +23.5% |
| 2022 | $85.06M | +48.8% |
| 2021 | $57.16M | +143.5% |
| 2020 | $23.47M | +219.3% |
| 2019 | $7.35M | - |